Cargando…
Benefits and harms of implementing [(18)F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study
BACKGROUND: [(18)F]-fluorodeoxyglucose-positron emission tomography/computed tomography ([(18)F]FDG-PET/CT) has been implemented sporadically in hospital settings as the standard of care examination for recurrent breast cancer. We aimed to explore the clinical impact of implementing [(18)F]FDG-PET/C...
Autores principales: | Vogsen, Marianne, Jensen, Jeanette Dupont, Gerke, Oke, Jylling, Anne Marie Bak, Asmussen, Jon Thor, Christensen, Ivar Yannick, Braad, Poul-Erik, Thye-Rønn, Peter, Søe, Katrine Lydolph, Ewertz, Marianne, Hildebrandt, Malene Grubbe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458550/ https://www.ncbi.nlm.nih.gov/pubmed/34553294 http://dx.doi.org/10.1186/s13550-021-00833-3 |
Ejemplares similares
-
2-[(18)F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer
por: Vogsen, Marianne, et al.
Publicado: (2023) -
Prognostic Value of Dual-Time-Point (18)F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2020) -
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
por: Hildebrandt, Malene Grubbe, et al.
Publicado: (2019) -
The Pattern of Metastatic Breast Cancer: A Prospective Head-to-Head Comparison of [(18)F]FDG-PET/CT and CE-CT
por: Gram-Nielsen, Rosa, et al.
Publicado: (2023) -
Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2021)